https://www.selleckchem.com/pr....oducts/marimastat.ht
6% and 1.3%, respectively. Corresponding results for Grade 3/4 neutropenia were 2.2% and 0.9%, respectively. Adverse drug reactions occurred in 24 patients (10.5%) those in more than one patient were bone pain (n=6, 2.6%) and pyrexia (n=3, 1.3%). The use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia was effective and well tolerated in patients with urological malignancies in the real-world setting.Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Va
Like
Comment
Share
